Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Open - Angle Glaucoma (POAG) Clear all
Completed No phase listed Observational Accepts healthy volunteers

How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?

NCT00626847
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Nov 4, 2026, 10:27 PM EST
Withdrawn Not applicable Interventional

IOP and Medication Reduction in MIGS Procedures

NCT04202510
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions
Glaucoma and Cataract Surgery
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 4, 2026, 10:27 PM EST
Terminated Not applicable Interventional Results available

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

NCT02928289
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT00809848
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2013 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Study of Safety of H1337 in Healthy Volunteers

NCT06572397
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 1.0%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 4, 2026, 10:27 PM EST
Completed No phase listed Observational Results available

PRESERFLO® MicroShunt Extension Study

NCT04333433
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
PRESERFLO® MicroShunt, Trabeculectomy
Device · Procedure
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
279 participants
Timeline
2020 – 2022
U.S. locations
19
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 4, 2026, 10:27 PM EST
Recruiting Not applicable Interventional

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

NCT07147647
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
Direct Selective Laser Trabeculoplasty
Device
Lead sponsor
Select Eye Care
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Elkridge, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

NCT04830397
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
QLS-101, Timolol Maleate
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albany, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Nov 4, 2026, 10:27 PM EST
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

NCT06822738
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
XEN63 Glaucoma Treatment System
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Culver City, California • Petaluma, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 1 Interventional Results available

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

NCT04360174
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
OTX-TIC
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Petaluma, California • Torrance, California • Roswell, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Nov 4, 2026, 10:27 PM EST
Terminated Not applicable Interventional

Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube

NCT01301378
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma, Traumatic Glaucoma, Uveitic Glaucoma, Neovascular Glaucoma
Interventions
Molteno 3 glaucoma drainage shunt
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Nov 4, 2026, 10:27 PM EST
Completed No phase listed Observational Accepts healthy volunteers

STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

NCT01442896
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Nov 4, 2026, 10:27 PM EST
Terminated Not applicable Interventional

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
Stents, Laser, Laser Trabeculoplasty
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Nov 4, 2026, 10:27 PM EST
Completed Not applicable Interventional Results available

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

NCT04629521
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Nov 4, 2026, 10:27 PM EST
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Nov 4, 2026, 10:27 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

NCT04465864
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Cataract
Interventions
Intracanalicular Dexamethasone, 0.4 mg insert
Drug
Lead sponsor
Wolstan and Goldberg Eye Associates
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional Results available

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions
PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Bimatoprost Ocular Insert

NCT02358369
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
10
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 3 Interventional

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Nov 4, 2026, 10:27 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT02805257
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions
Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
Drug · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 4, 2026, 10:27 PM EST